These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31204455)

  • 21. Clinical and laboratory evaluation of cured and non-cured patients with cutaneous leishmaniasis treated by Glucantime.
    Ezatkhah F; Sharifi I; Babaei Z; Baneshi MR; Zolala F; Kermanizadeh A; Keyhani A; Sharifi M; Dezaki ES; Aflatoonian MR; Aflatoonian B; Khatami M; Bamorovat M
    J Vector Borne Dis; 2019; 56(4):351-359. PubMed ID: 33269736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
    Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
    Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic zosteriform cutaneous leishmaniasis.
    Omidian M; Mapar MA
    Indian J Dermatol Venereol Leprol; 2006; 72(1):41-2. PubMed ID: 16481709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital.
    Garrido-Jareño M; Sahuquillo-Torralba A; Chouman-Arcas R; Castro-Hernández I; Molina-Moreno JM; Llavador-Ros M; Gómez-Ruiz MD; López-Hontangas JL; Botella-Estrada R; Salavert-Lleti M; Pemán-García J
    Parasit Vectors; 2020 Jan; 13(1):24. PubMed ID: 31931865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spatial analysis of cutaneous leishmaniasis in an endemic area of Iran based on environmental factors.
    Ramezankhani R; Sajjadi N; Nezakati Esmaeilzadeh R; Jozi SA; Shirzadi MR
    Geospat Health; 2017 Nov; 12(2):578. PubMed ID: 29239561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-western Iran.
    Askari A; Sharifi I; Aflatoonian MR; Babaei Z; Ghasemi Nejad Almani P; Mohammadi MA; Alizadeh H; Hemati S; Bamorovat M
    Microb Pathog; 2018 Aug; 121():363-368. PubMed ID: 29709689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
    Bamorovat M; Sharifi I; Fekri A; Keyhani A; Aflatoonian MR; Heshmatkhah A; Oliaee RT; Khosravi A; Naderi A; Parizi MH; Mostafavi M; Varma RS
    Microb Pathog; 2019 Mar; 128():162-170. PubMed ID: 30583021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
    Sadeghian G; Nilfroushzadeh MA; Iraji F
    Clin Exp Dermatol; 2007 Jul; 32(4):371-4. PubMed ID: 17376205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study.
    Ngouateu OB; Kollo P; Ravel C; Dereure J; Kamtchouing P; Same-Ekobo A; von Stebut E; Maurer M; Dondji B
    Trans R Soc Trop Med Hyg; 2012 Mar; 106(3):137-42. PubMed ID: 22301076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.
    Suprien C; Rocha PN; Teixeira M; Carvalho LP; Guimarães LH; Bonvoisin T; Machado PRL; Carvalho EM
    Am J Trop Med Hyg; 2020 Apr; 102(4):777-781. PubMed ID: 32043440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Outbreak of cutaneous leishmaniasis: about 213 cases in the province of Tizi-Ouzou].
    Achour Barchiche N; Madiou M
    Pathol Biol (Paris); 2009 Feb; 57(1):65-70. PubMed ID: 18849125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ecoepidemiological characteristics of a hypoendemic focus of zoonotic cutaneous leishmaniasis in north Iran (southeast of Caspian Sea).
    Agh-Atabay MD; Sofizadeh A; Ozbaki GM; Malaki-Ravasan N; Ghanbari MR; Mozafari O
    J Vector Borne Dis; 2016; 53(3):248-56. PubMed ID: 27681548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate.
    Shamsi Meymandi S; Zandi S; Aghaie H; Heshmatkhah A
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):587-91. PubMed ID: 20666876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new focus of cutaneous leishmaniasis caused by Leishmania tropica.
    Yaghoobi-Ershadi MR; Hanafi-Bojd AA; Javadian E; Jafari R; Zahraei-Ramazani AR; Mohebali M
    Saudi Med J; 2002 Mar; 23(3):291-4. PubMed ID: 11938418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
    Cataldo JI; Conceição-Silva F; Antônio LF; Schubach AO; Marzochi MCA; Valete-Rosalino CM; Pimentel MIF; Lyra MR; Oliveira RVC; Barros JHDS; Pacheco RDS; Madeira MF
    Rev Soc Bras Med Trop; 2018; 51(6):769-780. PubMed ID: 30517530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The increase in neglected cutaneous leishmaniasis in Gaziantep province of Turkey after mass human migration.
    Eroglu F; Ozgoztasi O
    Acta Trop; 2019 Apr; 192():138-143. PubMed ID: 30710533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.